Pembrolizumab/Keytruda

From Proteopedia

Jump to: navigation, search

Pembrolizumab Antibody Against PD-1 Receptor

Full-Length Crystal Structure of Pembrolizumab (PDB code 5dk3)

References

  1. 1.0 1.1 Longoria TC, Tewari KS. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma. Expert Opin Drug Metab Toxicol. 2016 Oct;12(10):1247-53. doi:, 10.1080/17425255.2016.1216976. Epub 2016 Aug 16. PMID:27485741 doi:http://dx.doi.org/10.1080/17425255.2016.1216976
  2. 2.0 2.1 2.2 2.3 Horita S, Nomura Y, Sato Y, Shimamura T, Iwata S, Nomura N. High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1. Sci Rep. 2016 Oct 13;6:35297. doi: 10.1038/srep35297. PMID:27734966 doi:http://dx.doi.org/10.1038/srep35297
  3. Rajakulendran T, Adam DN. Spotlight on pembrolizumab in the treatment of advanced melanoma. Drug Des Devel Ther. 2015 Jun 4;9:2883-6. doi: 10.2147/DDDT.S78036. eCollection, 2015. PMID:26082618 doi:http://dx.doi.org/10.2147/DDDT.S78036
  4. Deeks ED. Pembrolizumab: A Review in Advanced Melanoma. Drugs. 2016 Mar;76(3):375-86. doi: 10.1007/s40265-016-0543-x. PMID:26846323 doi:http://dx.doi.org/10.1007/s40265-016-0543-x

Melanie Kusakavitch was a contributing author.

Proteopedia Page Contributors and Editors (what is this?)

Emily Bradshaw., Michal Harel

Personal tools